Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension
World Journal of Gastrointestinal Oncology · 15.08.2026 · 18 (8)
DOI: 10.4251/wjgo.118698 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.08.2026. Verfasst von Hua-Cheng Lou und 4 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with postoperative adjuvant chemotherapy being crucial for stage III patients. Hypertension is a prevalent comorbidity, yet the interaction between antihypertensive agents and chemotherapeutics remains unclear. While calcium channel blockers like amlodipine may modulate tumor metabolism and enzyme expression, the renin-angiotensin system inhibitors like valsartan may influence angiogenesis. However, direct clinical comparisons regarding their impact on capecitabine efficacy are lacking. We hypothesized that amlodipine, compared to valsartan, would demonstrate superior efficacy in reducing tumor markers when combined with capecitabine in hypertensive CRC patients. AIM To compare amlodipine vs valsartan combined with capecitabine in hypertensive stage III CRC patients. METHODS This retrospective controlled study enrolled 120 stage III CRC patients with hypertension were selected from January 2023 to November 2024. Patients were allocated to either the experimental group (capecitabine plus amlodipine, n = 60) or the control group (capecitabine plus valsartan, n = 60). The intervention duration was 8-12 cycles. Blood pressure, tumor markers [carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9)], and adverse events were compared using t -tests, χ ² tests, and two-way repeated-measures analysis of variance. RESULTS Following treatment, the reductions in systolic blood pressure (119.04 ± 10.44 mmHg) and diastolic blood pressure (78.90 ± 4.23 mmHg) were markedly greater in the experimental group than the control group (P < 0.001). The decreases in CEA and CA19-9 levels were greater in the experimental group. Repeated-measures analysis of variance confirmed significant time × group interactions (CEA: P = 0.048; CA19-9: P = 0.036). There was no clinically relevant difference in the frequency of adverse reactions between the two groups (P > 0.05), with adverse events being predominantly grade 1-2 in both. CONCLUSION Amlodipine combined with capecitabine yields superior blood pressure control and greater reductions in CEA/CA19-9 than valsartan, with a comparable safety profile, but survival endpoint confirmation is required.
Zitieren
APA
Lou, H., Liu, X., Jin, P., Wang, J., & Liu, B. (2026). Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension. World Journal of Gastrointestinal Oncology, 18(8). https://doi.org/10.4251/wjgo.118698
Vancouver
Lou H, Liu X, Jin P, Wang J, Liu B. Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension. World Journal of Gastrointestinal Oncology. 2026;18(8). doi:10.4251/wjgo.118698
BibTeX
@article{Lou2026,
author = {Lou, Hua-Cheng and Liu, Xiao-Hua and Jin, Ping and Wang, Jian-Min and Liu, Bin},
title = {Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
volume = {18},
number = {8},
doi = {10.4251/wjgo.118698}
}
EUVIMED